Philip A Thompson

Trials

Studies that name Philip A Thompson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:58 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03121534 · Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

  M.D. Anderson Cancer Center · terminated · Hematopoietic/Lymphoid Cancer, Richter's Transformation · principal investigator
• Ph2
  NCT02906696 · Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

  M.D. Anderson Cancer Center · terminated · Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
  Named on NCT02906696